Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

e development of treatments for rare pediatric diseases.  Companies that receive a voucher may use it or transfer the voucher, including by sale, to other organizations.

About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs.  Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York, that discovers, invents, develops, manufactures, and commercializes biologic medicines for the treatment of serious medical conditions.  Regeneron commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts.  These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.  Forward-looking statements are gene
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Investor-Edge has initiated coverage on ... ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), ... Pharmaceuticals Inc. (NASDAQ: PPHM ), and StemCells ... can be accessed at: http://investor-edge.com/register . ... on a positive note as the Dow Jones Industrial ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Khaimah, UAE (PRWEB) October 22, 2014 ... life science and healthcare projects, announces the addition of ... DRCOG DCH to its advisory team. Dr. Siddiqui will ... team. , A graduate of University College ... was subsequently degreed in medicine in 2001. With further ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2
... Guide, ,I. Description ,II. Product Components ... ,IV. Protocol for Extraction of DNA from Whole Blood ... Whole Blood ,VI. Quantification of Amplified Products ... Application Data , References , Contact Information ...
... ,I. Description ,II. Product Components ,III. ... Protocol for Extraction of DNA from Blood Card ... Card ,VI. Quantification of Amplified Products ,VII. ... , References , Contact Information , , ,Application ...
... , , ... , , , Mutations ... of the colon, pancreas, liver, spleen, stomach or lungs. The,CDKN2A/P16 gene is ... which point mutation is present,in patient tissue samples. Freshly frozen tumor sections ...
Cached Biology Technology:Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 2Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 3Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 4Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 5Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 6Protocol for GenomePlex Whole Genome Amplification from Blood Card 2Protocol for GenomePlex Whole Genome Amplification from Blood Card 3Protocol for GenomePlex Whole Genome Amplification from Blood Card 4Protocol for GenomePlex Whole Genome Amplification from Blood Card 5Protocol for GenomePlex Whole Genome Amplification from Blood Card 6Mutation detection for the,K- rasand P16 genes 2Mutation detection for the,K- rasand P16 genes 3Mutation detection for the,K- rasand P16 genes 4Mutation detection for the,K- rasand P16 genes 5Mutation detection for the,K- rasand P16 genes 6
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... Oregon and Washington land managers have a new synthesis ... eastside moist mixed-conifer (MMC) forests in the two states. ... Forests in Eastern Oregon and Washington: A Synthesis of ... Management, a general technical report published by the U.S. ... response to a request from managers for a synthesis ...
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... A tiny wasp that lays its eggs under the ... most diverse groups of insects on Earth. Now researchers ... thought. (To see an audio slide show on ... By combining ecological and genetic data with the painstaking ...
... risk during cardiac procedures. Doctors performing heart surgery also ... IAEA is helping to raise awareness of threats, through ... X-ray imaging systems. The issue of radiation protection ... of lengthy angioplasty and other cardiac interventions performed under ...
... insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts ... treatment, said researchers at Baylor College of Medicine in a ... Journal of Clinical Oncology. The finding gives impetus to ... various tumors. "These findings come at a critical time," ...
Cached Biology News:Diversity among parasitic wasps is even greater than suspected 2Diversity among parasitic wasps is even greater than suspected 3Protecting those who heal 2Growth factor predicts poor outcome in breast cancer 2
6B9...
... DNA polymerase from Thermus aquaticus expressed in ... 1 tube of 250 units enzyme/tube and ... DNA), is the same enzyme as AmpliTaq ... a proprietary separation process to ensure that ...
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' ... DNA polymerase which exhibits very high activity ... applications. To ensure the quality of the ...
... AmpliTaq DNA Polymerase is the most thoroughly ... a testimony to its overall utility and ... it ideal for PCR applications. , ... results. ,, AmpliTaq DNA Polymerase is ...
Biology Products: